Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real‐World Evidence Study
International Journal of Urology · 2025
DOI: 10.1111/iju.70023 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2025. Verfasst von Alicia K Morgans und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Antibodies, Monoclonal, Patient Acceptance of Health Care. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Seagen, Astellas Pharma Inc., Astellas Pharma.
Abstract (Originalsprache)
Objective
To describe real‐world patient characteristics, prior treatment patterns, and associated healthcare resource utilization (HRU) and costs among patients with locally advanced/metastatic urothelial carcinoma (la/mUC) treated with enfortumab vedotin (EV).
Methods
This retrospective study used the United States (US) Centers for Medicare and Medicaid Services 100% Medicare claims data from 2015 to 2020. Included patients had a diagnosis of la/mUC and received treatment with EV. The index date was the EV initiation date. Endpoints included HRU and costs 12 months before the index date (baseline period) and treatment patterns before EV initiation. Results were summarized descriptively using means and standard deviations for continuous variables, and frequency counts and percentages for categorical variables.
Results
Among the 529 included patients, the mean age at the time of EV initiation was 76.5 years. Most patients were White (88.1%) and male (77.1%). Common comorbidities were hypertension (85.1%), renal disease (65.2%), and peripheral vascular disease (42.5%). Platinum‐based chemotherapy was the most frequent therapy two lines before EV initiation (43.9%). The most frequent therapy in the line before EV initiation was PD‐1/L1 inhibitors (61.4%). The median duration of EV therapy was 4.1 months. The mean all‐cause healthcare cost during the baseline period was $106 258 per patient, and 86% had at least one outpatient visit.
Conclusions
This real‐world study demonstrated that most US patients with la/mUC received platinum‐based chemotherapy or a PD‐1/L1 inhibitor prior to EV therapy from 2015 to 2020. HRU and costs 12 months before EV initiation suggest a substantial burden in this population. Long‐term studies with more recent data are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Astellas Pharma, Inc., Northbrook, Illinois, USA.
- Pfizer, New York, New York, USA.
- Analysis Group, Boston, Massachusetts, USA.
- Analysis Group, New York, New York, USA.
Förderung
- Seagen
- Astellas Pharma Inc.
- Astellas Pharma
Zitieren
APA
Morgans, A. K., Mucha, L., Quicquaro, C., Shih, V., Xie, B., Young, C., Yang, H., Liu, Q., Greatsinger, A., & Lax, A. (2025). Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real‐World Evidence Study. International Journal of Urology. https://doi.org/10.1111/iju.70023
Vancouver
Morgans AK, Mucha L, Quicquaro C, Shih V, Xie B, Young C, et al. Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real‐World Evidence Study. International Journal of Urology. 2025. doi:10.1111/iju.70023
BibTeX
@article{Morgans2025,
author = {Morgans, Alicia K and Mucha, Lisa and Quicquaro, Christina and Shih, Vanessa and Xie, Bin and Young, Christopher and Yang, Hongbo and Liu, Qing and Greatsinger, Alexandra and Lax, Angela},
title = {Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real‐World Evidence Study},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.70023}
}
EUVIMED